James D Neaton
Overview
Explore the profile of James D Neaton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
171
Citations
12937
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Davey Jr R, Collins G, Rouphael N, Poliquin G, McConnell R, Grubbs G, et al.
Lancet Microbe
. 2024 Oct;
5(11):100923.
PMID: 39374605
Background: rVSVΔG-ZEBOV-GP is the first approved vaccine with clinical efficacy against Ebola virus disease. Although a seroprotective threshold has not been defined for those at occupational risk of exposure, the...
2.
Fallah M, Reilly C, Van Ryn C, Badio M, Camanor S, Kaler S, et al.
Lancet Glob Health
. 2023 Jun;
11(7):e1053-e1060.
PMID: 37349033
Background: Minimal data exist on pregnancy following recovery from Ebola in people of child-bearing potential (females aged roughly 18-45 years). The aim of this study was to assess viral persistence...
3.
Brown S, Barkauskas C, Grund B, Sharma S, Phillips A, Leither L, et al.
Lancet Respir Med
. 2023 Jun;
11(9):791-803.
PMID: 37348524
Background: There is a clinical need for therapeutics for COVID-19 patients with acute hypoxemic respiratory failure whose 60-day mortality remains at 30-50%. Aviptadil, a lung-protective neuropeptide, and remdesivir, a nucleotide...
4.
Safo S, Haine L, Baker J, Reilly C, Duprez D, Neaton J, et al.
J Am Heart Assoc
. 2023 Jun;
12(13):e027273.
PMID: 37345752
Background Cardiovascular disease risk prediction models underestimate CVD risk in people living with HIV (PLWH). Our goal is to derive a risk score based on protein biomarkers that could be...
5.
Vanderven H, Wentworth D, Han W, Peck H, Barr I, Davey Jr R, et al.
JCI Insight
. 2023 Jun;
8(14).
PMID: 37289541
BACKGROUNDAntibody-based therapies for respiratory viruses are of increasing importance. The INSIGHT 006 trial administered anti-influenza hyperimmune intravenous immunoglobulin (Flu-IVIG) to patients hospitalized with influenza. Flu-IVIG treatment improved outcomes in patients...
6.
Lundgren J, Babiker A, Sharma S, Grund B, Phillips A, Matthews G, et al.
NEJM Evid
. 2023 May;
2(3).
PMID: 37213438
Background: For people with HIV and CD4 counts >500 cells/mm, early initiation of antiretroviral therapy (ART) reduces serious AIDS and serious non-AIDS (SNA) risk compared with deferral of treatment until...
7.
Bonner K, Chyderiotis S, Sicsic J, Mueller J, Ulrich A, Toomey T, et al.
SSM Popul Health
. 2023 Apr;
22:101384.
PMID: 37008807
Seasonal influenza vaccination rates remain low, and contribute to preventable influenza cases, hospitalizations, and deaths in the US. While numerous interventions have been implemented to increase vaccine uptake, there is...
8.
Fallah M, Lane H, Higgs E, Kennedy S, Massaquoi M, Kieh M, et al.
Lancet Glob Health
. 2023 Feb;
11(3):e321-e323.
PMID: 36796971
No abstract available.
9.
Rogers A, Wentworth D, Phillips A, Shaw-Saliba K, Dewar R, Aggarwal N, et al.
Ann Intern Med
. 2022 Aug;
175(10):1401-1410.
PMID: 36037469
Background: Levels of plasma SARS-CoV-2 nucleocapsid (N) antigen may be an important biomarker in patients with COVID-19 and enhance our understanding of the pathogenesis of COVID-19. Objective: To evaluate whether...
10.
Mylonakis E, Lutaakome J, Jain M, Rogers A, Molto J, Benet S, et al.
Med
. 2022 Aug;
3(8):531-537.
PMID: 35963234
The protection provided by natural versus hybrid immunity from COVID-19 is unclear. We reflect on the challenges from trying to conduct a randomized post-SARS-CoV-2 infection vaccination trial study with rapidly...